key: cord-0925716-e3pgjmhn
authors: Marín-Palma, Damariz; Tabares-Guevara, Jorge H.; Zapata-Cardona, María I.; Flórez-Álvarez, Lizdany; Yepes, Lina M.; Rugeles, Maria T.; Zapata-Builes, Wildeman; Hernandez, Juan C.; Taborda, Natalia A.
title: Curcumin Inhibits In Vitro SARS-CoV-2 Infection In Vero E6 Cells through Multiple Antiviral Mechanisms
date: 2021-11-16
journal: Molecules
DOI: 10.3390/molecules26226900
sha: f499c8b17f5814d9712e8c77ebdffa49d5b53538
doc_id: 925716
cord_uid: e3pgjmhn

Due to the scarcity of therapeutic approaches for COVID-19, we investigated the antiviral and anti-inflammatory properties of curcumin against SARS-CoV-2 using in vitro models. The cytotoxicity of curcumin was evaluated using MTT assay in Vero E6 cells. The antiviral activity of this compound against SARS-CoV-2 was evaluated using four treatment strategies (i. pre–post infection treatment, ii. co-treatment, iii. pre-infection, and iv. post-infection). The D614G strain and Delta variant of SARS-CoV-2 were used, and the viral titer was quantified by plaque assay. The anti-inflammatory effect was evaluated in peripheral blood mononuclear cells (PBMCs) using qPCR and ELISA. By pre–post infection treatment, Curcumin (10 µg/mL) exhibited antiviral effect of 99% and 99.8% against DG614 strain and Delta variant, respectively. Curcumin also inhibited D614G strain by pre-infection and post-infection treatment. In addition, curcumin showed a virucidal effect against D614G strain and Delta variant. Finally, the pro-inflammatory cytokines (IL-1β, IL-6, and IL-8) released by PBMCs triggered by SARS-CoV-2 were decreased after treatment with curcumin. Our results suggest that curcumin affects the SARS-CoV-2 replicative cycle and exhibits virucidal effect with a variant/strain independent antiviral effect and immune-modulatory properties. This is the first study that showed a combined (antiviral/anti-inflammatory) effect of curcumin during SARS-CoV-2 infection. However, additional studies are required to define its use as a treatment for the COVID-19.

Since March 2020, the World Health Organization (WHO) has declared COVID-19 as a pandemic [1] . The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is an enveloped virus consisting of a positive-sense single-stranded RNA genome [2] . According to phylogenetic analysis, SARS-CoV-2 is a new member of the Betacoronavirus genus [3] [4] [5] , which can infect humans and diverse animal species [6] . This virus is highly pathogenic and mainly affects respiratory tract cells, causing respiratory disease that can develop into severe, even life-threatening, pathologies. The SARS-CoV-2 genome encodes nonstructural, structural, and accessory proteins [6] , which play essential roles within the viral replicative cycle [7] [8] [9] . Spike protein, 3C-like protease (3CLpro), papain-like cysteine protease (PLpro), and RNA-dependent RNA polymerase (RdRp) are the main antiviral targets [10] .

Curcumin was cytotoxic at 20 and 40 µg/mL (cell viability of 21.4% and 9.34%, respectively) after 48 h of treatment on Vero E6. Contrarily, the viability of Vero E6 was higher or equal to 80% at curcumin concentrations of 10 µg/mL or lower ( Figure 1 ). The CC50 (50% cytotoxic concentration) obtained for curcumin was 16.5 µg/mL. Positive controls of viral inhibition (chloroquine and heparin) did not affect cell viability at the evaluated concentrations ( Figure 2 ). 

The antiviral effect of non-cytotoxic concentrations of curcumin (1.25-10 µg/mL) were evaluated through four treatment strategies and using a MOI of 0.01. By pre-post infection treatment (cells treatment with curcumin, prior and post to infection with SARS-CoV-2) curcumin exerted antiviral activity of 99.0% (p = 0.0095), 51.3% (p = 0.0095), 22 .2% (p = 0.0095), and 27.8% (p = 0.0095) against SARS-CoV-2 D614G strain at concentrations of 10, 5, 2.5, and 1.25 µg/mL, respectively ( Figure 3 ). An EC50 (50% maximal effective concentration) of 4.06 µg/mL (3.09-5.16 µg/mL) was calculated for curcumin, with an SI (Selectivity Index) of 4.06 (Table 1) , by pre-post infection treatment. An inhibition of 100% (p = 0.0095) was observed for chloroquine treatment (positive control of viral inhibition) ( Figure 3 ). (B) The figure shows the reduction of D614G strain titer (PFU/mL) on Vero E6 supernatants after pre-post infection treatment with curcumin (n = 4). Chloroquine (CQ) was included as a positive control of viral inhibition. Data were presented as median ± IQR (interquartile range). Mann-Whitney test ** p ≤ 0.01. Inhibition percentages of 99%, 51.3%, 22.2%, and 27.8% were obtained at 10, 5, 2.5, and 1.25 µg/mL of curcumin, respectively. (C) Representative plaques on Vero E6 cells of pre-post infection treatment of curcumin against D614G strain. Then, the pre-infection and post-infection treatment strategies were performed to identify the steps of the SARS-CoV-2 replicative cycle affected by curcumin. The preinfection treatment demonstrated that curcumin had an antiviral effect against SARS-CoV-2 D614G strain at 10 µg/mL of 99.2%, p = 0.0095 and at 5 µg/mL of 39.3%, p = 0.0095 ( Figure 4 ). Differences in viral titer were not observed at 2.5 and 1.25 µg/mL of curcumin. The EC50 value calculated for curcumin was 5.02 µg/mL, with an SI of 3.29, by the preinfection treatment. Heparin was used as a positive control of viral inhibition. Data were presented as median ± IQR (n = 4). Mann-Whitney test ** p ≤ 0.01. Inhibition percentages of 99.2%, 39.3%, −12.8%, and −0.4% were obtained at 10, 5, 2.5, and 1.25 µg/mL of curcumin, respectively. (C) Representative plaques on Vero E6 cells of pre-treatment of curcumin against D614G strain.

After the post-infection treatment, curcumin exerted an antiviral effect against SARS-CoV-2 D614G strain at 10 µg/mL of 84.4%, p = 0.0095, and at 5 µg/mL of 31.7%, p = 0.0095 ( Figure 5 ). However, inhibitions of 21.9% and 14.8% were observed at 2.5 and 1.25 µg/mL of curcumin, respectively. The EC50 value calculated for curcumin was 6.03 µg/mL (4.83-7.41 µg/mL), with an SI of 2.74, by the post-infection treatment. Heparin and chloroquine were the positive controls for viral inhibition in the preinfection and post-infection treatments, respectively. From the pre-infection treatment, an inhibition percentage of 87.6% (p = 0.0095) was obtained at 25 µg/mL of heparin (Figure 4) , whereas an inhibition of 99.3% (p = 0.0095) was obtained by post-infection treatment with chloroquine ( Figure 5 ).

As can be seen from Figure 6 , the viral titer of D614G strain was significantly reduced through co-treatment strategy (incubation of curcumin with the virus prior to infection) at 10 (92%, p = 0.004), 5 (60.4%, p = 0.004), and 2.5 µg/mL (39.3%, p = 0.004) of curcumin ( Figure 6 ). An inhibition of 2.3% was obtained at 1.3 µg/mL. An EC50 of 3.57 µg/mL (3.06-4.17 µg/mL) was calculated for curcumin, with an SI of 4.62, from co-treatment. Finally, an inhibition percentage of 83% (p = 0.004) was observed by co-treatment with chloroquine (positive control of viral inhibition) ( Figure 6 ). The figure represents the reduction of D614G strain titer (PFU/mL) on Vero E6 supernatants after co-treatment treatment with curcumin (from 1.25 to 10 µg/mL). Chloroquine (CQ) was used as a positive control of viral inhibition. Data were presented as median ± IQR (n = 4). Mann-Whitney test ** p ≤ 0.01. Inhibition percentages of 92%, 60.4%, 39.3%, and 2.3% were obtained at 10, 5, 2.5, and 1.25 µg/mL of curcumin, respectively. (C) Representative plaques on Vero E6 cells of the co-treatment strategy of curcumin against SARS-CoV-2 D614G strain.

Considering that curcumin showed inhibition in all treatment strategies, this compound was evaluated against infection by the SARS-CoV-2 Delta variant using pre-post infection and co-treatment. As shown in the Figure 7A ,B, curcumin inhibited Delta variant at 10 µg/mL (99.8%, p = 0.0007), 5 (98.4%, p = 0.0007), 2.5 (98.9%, p = 0.0007), and 1.25 µg/mL (62.9%, p = 0.0007), by pre-post infection treatment (EC50 = 1.14 µg/mL, SI = 14.5). In addition, curcumin showed antiviral activity of 99.9% (p = 0.0012), 99.1% (p = 0.0012), 31.9% (p = 0.0233), and 56.5% (p = 0.0017) against Delta variant, at concentrations of 10, 5, 2.5, and 1.25 µg/mL, respectively, using a co-treatment strategy. The EC50 value calculated for curcumin was 1.66 µg/mL, with an SI of 9.94, by the co-treatment ( Figure 7C ,D). These results indicated that the anti-SARS-CoV-2 effect of curcumin was not dependent on the infecting strain/variant. Chloroquine (positive control of viral inhibition) showed antiviral activity against the Delta variant using pre-post infection treatment (100%, p = 0.0007) and co-treatment (100%, p = 0.0002) (Figure 7 ). 

To evaluate the potential anti-inflammatory effect of curcumin on SARS-CoV-2 infection, PBMCs were pretreated with curcumin and stimulated with SARS-CoV-2 at 0.1 MOI in 50 µL of RPMI supplemented with 5% FBS for 24 h. After, the cells and supernatants were collected for cytokine (mRNA and protein) quantification. Significant decreases in IL-1β mRNA (p = 0.0022, Figure 8A ), IL-6 mRNA (p < 0.001, Figure 8B ), IL-8 mRNA (p = 0.0022, Figure 8C ), and MCP-1 mRNA (p = 0.0050) were found in PBMCs pretreated with 10 µg/mL of curcumin compared with cells stimulated only with the virus. No significant changes in the mRNA expression of TNF-α was found ( Figure 8D ). Similarly, a decrease in IL-1β (p < 0.0001, Figure 9A ), IL-6 (p = 0.0022, Figure 9B ) and IL-8 (p = 0.0022, Figure 9C ) protein levels determined by ELISA was observed in the supernatant from PBMCs pretreated with 10 µg/mL of curcumin compared to cells stimulated only with the virus. Cells untreated were used as a negative control. Data were represented as median ± IQR (n = 6). Mann-Whitney test ** p ≤ 0.01, *** p ≤ 0.001.

There is still no conclusive information on the effectiveness of approved drugs for COVID-19 treatment, therefore, the discovery of effective and nontoxic antiviral agents is still necessary. Curcumin has shown a wide range of antiviral activity against different viral models [31] . Similar to these reports, our findings indicated that curcumin inhibits SARS-CoV-2 D614G strain which contains the most widespread amino acid change (D614G in the spike protein) carried by more than 99% of the prevalent variants since the beginning of 2020 [32, 33] . According to previous reports, curcumin exhibited moderate selectivity for pre-infection and post-infection treatment strategies. Contrarily, low selectivity was obtained for pre-post infection treatment and co-treatment strategies [34] .

Curcumin inhibited SARS-CoV-2 D614G strain by pre-infection treatment of Vero E6 cells. This effect has also been observed with other enveloped viruses such as Influenza, Dengue, Zika, Chikungunya, Japanese encephalitis, Pseudorabies, and Vesicular stomatitis virus [24, 35, 36] , showing that curcumin treatment affects the early stages of the replicative cycle, such as viral attachment, internalization, fusion, or decapsidation [37] . With regard to SARS-CoV-2, spike protein binds to its human receptor ACE2 (angiotensin-converting enzyme 2) through its receptor-binding domain [28, 29] . Previous studies have reported a favorable binding affinity of curcumin to the spike protein (−7.9 Kcal/mol) and its cell receptor, ACE2 (angiotensin-converting enzyme 2) (−7.8 Kcal/mol) [28] . According to the above, it could be suggested that curcumin prevents the recognition of the target cell and subsequent SARS-CoV-2 entry by direct interaction with cell factors or viral proteins [28, 38, 39] . This effect could be related to our results obtained by co-treatment which suggest a possible virucidal activity of curcumin against SARS-CoV-2 D614G strain.

Thus, this compound may directly interfere with structural glycoproteins or other viral envelope components that affect viral infectivity, as previously reported for Influenza virus [35, 40] and respiratory syncytial virus. Furthermore, treatment with curcumin could induce changes in the morphology of the SARS-CoV-2 viral particle, as reported for Murine norovirus-1 [41] . However, further studies are necessary to confirm the antiviral mechanism of this compound.

On the other hand, the membrane fusion stage requires the cleavage of the spike protein by cellular proteases [42] . This process occurs through the activation of TMPRSS2 (transmembrane serine protease 2) on the cell membrane or by the priming cathepsin B/L in the endosomes [29, 30, 43] . This last route depends on pH [29, 30] . With respect to this, a study reported that curcumin inhibits cellular protease TMPRSS2 (Trans-Membrane Serine Protease 2), which cleaves to the S2 subunit of spike protein to reveal the fusion peptide [29, 39] . In addition, it was demonstrated that this compound inhibits vacuolar-ATPase expression, which acts as a proton pump during the acidification of vesicles [44] . According to these studies, the mechanism of anti-SARS-CoV-2 activity of curcumin could involve the inactivation of cell enzymes participating in viral fusion with host membranes, thus blocking viral entry.

The post-infection treatment results indicates that curcumin can effectively inhibit SARS-CoV-2 D614G strain up to 87%, affecting the post-entry steps of the viral replicative cycle. Previously, it has been reported that curcumin inhibits SARS-CoV at a range of 3-10 µM, similar to our results [45] . It has also been reported that curcumin has a specific inhibitory effect on 3CL protease observed using the FRET method with a reported IC50 of 40 µM [45] . Furthermore, the antiviral activity of curcumin has been reported for other viruses, such as respiratory syncytial virus, where curcumin inhibits replication and budding, and HIV, where curcumin was shown to interact with active sites of protease and integrase [46, 47] . In the case of SARS-CoV-2, docking analysis has shown that curcumin has low binding energies and inhibition constants [48] , suggesting that this might be a potential mechanism of curcumin antiviral effect observed in this study. For example, it has been shown that curcumin exhibited multiple interactions with the Nsp9 replicase, which can directly affect viral replication [49] .

Taking into account that curcumin exhibited inhibition against D614G strain, through different treatment strategies, this compound was evaluated against infection by the Delta variant [50] which contains mutations in the spike protein (L452R, T478K, P681R, and D614G) associated with an increase in viral infectivity, transmissibility and pathogenicity in individuals infected with SARS-CoV-2 and a decrease in antibody-mediated neutralization [50] . Similar to that reported for PRRSV (porcine reproductive and respiratory syndrome virus) [51] , our results showed that the antiviral effect of curcumin is virus strain/variant independent. In this context, curcumin inhibited the Delta variant up to 99.9%, exhibiting higher selectivity than the obtained for D614G strain, through pre-post infection and co-treatment strategies. This finding is particularly important because antiviral drugs that are aimed at a conserved viral target could not only help reduce the possibility of the disease progressing to serious illness, but could also be used as a prophylactic strategy, helping to solve the problem of reduced response of variants to vaccines [52] .

According to the results obtained in vitro, we suggest the importance of evaluating the antiviral activity of curcumin in other cell lines, such as Calu-3 or A549 cells transfected with human ACE2 gene [53] , which are permissive for SARS-CoV-2 infection [53] .

The hyperactivation of immune cells and anomalous release of cytokines play a foremost role in poor outcomes in several viral diseases, including COVID-19. Such a systemic production of cytokines is often referred to as a cytokine storm [54] . This elevation in cytokine levels has been linked as the culprit behind deterioration and multiple organ failure in COVID-19 [55] . In this study, curcumin-treated PBMCs stimulated with SARS-CoV-2 exhibited a reduction in the production and release of pro-inflammatory cytokines, including IL-1β, IL-6, MCP-1, and IL-8. Similar results have been reported for COVID-19 patients treated with nano-curcumin (nano-micells or nano-particles formulation to encapsulate curcumin) [56] . The anti-inflammatory capacity of curcumin and its potential for use in treating viral infections, including coronavirus infections, have been hypothesized previously [56] . Activation of C-terminal leucine-rich repeats and NLRP3 inflammasome through downstream signaling of Toll-like receptor (TLRs) encourages maturation and release of proinflammatory cytokines. Moreover, TLRs activate NF-κB, which prompts the transcriptional activation of cytokines and other inflammatory molecules [57] . Therefore, previous reports indicate the downregulation of TLRs by curcumin [58] . In addition to TLRs, it has been shown that curcumin can diminish NF-κB activation [59] , as well as inhibit the NLRP3 inflammasome [60] , which could play a significant role in the development and progression of COVID-19.

Further, it has been persistently reported that curcumin has anti-inflammatory effects on in vivo models, such as atherosclerosis, multiple sclerosis, Alzheimer's, or arthritis [56, [61] [62] [63] [64] [65] . These studies demonstrated that curcumin blocks inflammation in parts by preventing the activation of macrophages and lymphocytes and inhibiting the production of pro-inflammatory cytokines and chemokines [65] [66] [67] . In this sense, it has been shown that despite the low bioavailability of curcumin, in two models of chronic disease, this compound has anti-inflammatory effects at low doses, via IL-10 production [68] .

Moreover, the ability of curcumin to alter the inflammatory state through the modulation of its regulatory elements can prevent the onset of the cytokine storm. The modulation of the cytokine release in SARS-CoV-2-infected patients can be crucial in the prevention of severe disease. Evidence presented in this article suggests that curcumin represents a promising compound for developing therapy against SARS-CoV2.

In this study, curcumin showed high cytotoxicity at 20 µg/mL in Vero E6 cells. However, the above minimal toxicity has been reported for this compound at doses of up to 8000 mg in humans [69] . This evidence shows that the toxicity obtained from these compounds through in vitro assays does not always overlap with that obtained from in vivo evaluations [70] . These differences could be related to the exposure time and supplementation with other compounds for their administration in humans [70, 71] . Based on the above, our study enables us to make an approximation to the effect of this compound as an antiviral; however, it is important to evaluate the toxicity of curcumin when its antiviral effect is determined through in vivo models to ensure the safety of this compound.

In conclusion, curcumin showed in vitro antiviral activity against SARS-CoV-2, with different treatment strategies, which suggest the inhibition at different stages of the replicative cycle; furthermore, these effects seem to be independent of the virus strain/variant. This antiviral effect, together with the observed immunomodulatory properties, suggests that curcumin could be a promising compound for the treatment of COVID-19 patients. However, complementary studies are necessary to establish its efficacy in animal and human models, as well as its mechanisms of action.

Cercopithecus aethiops kidney cell line Vero E6 was grown in Dulbecco s Modified Eagle Medium (DMEM, Sigma-Aldrich, St. Louis, MO, USA) supplemented with 2% heat-inactivated fetal bovine serum (FBS) (GIBCO), 1% penicillin-streptomycin (GIBCO), and 2 mM L-glutamine (Sigma-Aldrich) at 37 • C with 5% CO 2 . With three passages per week. Vero E6 cells were donated by Instituto Nacional de Salud, Bogotá-Colombia (Dr. José Usme, 11 April 2020). Infections were carried out with viral stocks produced from two Colombian SARS-CoV-2 isolates: D614G strain (EPI_ISL_536399) [72] and Delta variant (EPI_ISL_5103929).

Curcumin was purchased from MERCK (Item No. C1386; Darmstadt, Germany). Curcumin powder was solubilized in dimethyl sulfoxide (DMSO; Sigma, D-2650, Darmstadt, Germany) at 10 mg/mL. The stock was maintained at 4 • C protected from light until use. The working solution was prepared, diluting the stock at 40 µg/mL in DMEM supplemented with 2% FBS.

The cytotoxicity of curcumin on Vero E6 cells was evaluated using an MTT assay [73] . Briefly, Vero E6 cells were seeded in 96-well plates at a density of 1.0 × 10 4 cells/well in DMEM supplemented with 2% FBS. The plates were incubated for 24 h at 37 • C with 5% CO 2 . After incubation,100 µL/well of serial double dilutions of curcumin ranging from 1.25 to 40 µg/mL was added to cell monolayers and incubated for 48 h. Subsequently, the supernatant was removed, the cells were washed twice with phosphate buffered saline (PBS) (Lonza, Basel, Switzerland), and 30 µL/well of MTT (2 mg/mL) was added. After the addition of MTT, the plates were incubated for 2 h at 37 • C, with 5% CO 2, protected from light. Finally, 100 µL/well of DMSO was added. Plates were read at 570 nm using a Multiskan TM GO Microplate Spectrophotometer (Thermo-Scientific, Waltham, MA, USA). The average absorbance of untreated cells was used as viability control. The cell viability of each treated well was calculated based on the viability control. Concentrations with cell viability after treatment of 80% or more were considered non-cytotoxic. For the MTT assay, two independent experiments with four replicates each were conducted (n = 8).

The antiviral activity of curcumin was initially evaluated using a pre-post infection treatment strategy [74] . Briefly, Vero E6 cells were seeded in 96-well plates (1.2 × 10 4 cells/well) and incubated for 24 h, at 37 • C with 5% CO 2 . Then, serial double dilutions of curcumin (from 1.25 to 10 µg/mL) were prepared and added to cell monolayers (50 µL/well) for 1 h. After pretreatment, the curcumin-containing medium was aspirated from cell monolayers, and the virus was added at 0.01 MOI (multiplicity of infection) in 50 µL of DMEM supplemented with 2% FBS. After 1 h of viral adsorption at 37 • C, the inoculum was removed and replaced by 150 µL/well of the same pre-treatment dilutions. Finally, the plates were incubated for 48 h at 37 • C under a 5% CO 2 atmosphere.

To determinate which steps of the viral cycle are being affected by curcumin treatment, the antiviral activity was evaluated using three extra strategies: (i) Co-treatment: Serial double dilutions of curcumin were mixed with SARS-CoV-2 (MOI 0.01) and incubated for 1 h at 37 • C (1:1 ratio). After incubation, 50 µL/well of the virus-treatment mixture was added to cell monolayers and incubated at 37 • C for 1 h. After 1 h of viral adsorption, the mixture (curcumin-virus) was removed and replaced by 150 µL/well of fresh medium. The plates were incubated for 48 h at 37 • C with 5% CO 2 . (ii) Pre-infection treatment: 150 µL/well of serial double dilutions of curcumin was added to cell monolayers for 24 h before viral infection. (iii) Post-infection treatment: 150 µL/well of serial double dilutions of curcumin was added to cell monolayers for 48 h after infection. In all cases, two independent experiments with four replicas each were performed (n = 8). Chloroquine (100 µM) [75] or heparin (25 µg/mL) [76] were used as positive controls of viral inhibition.

The viral titer of antiviral assay supernatants was determined by plaque assay. Briefly, 1.2 × 10 5 Vero E6 cells/well were seeded in 24-well plates for 24 h, at 37 • C, with 5% CO 2 . Subsequently, 10-fold serial dilutions of the supernatant obtained from all antiviral assays (200 µL/well) were added to cell monolayers and incubated for 1 h at 37 • C with 5% CO 2 . Then, the viral inoculum was removed and replaced with 1 mL of semi-solid medium (1.5% carboxymethyl-cellulose in DMEM 1× with 2% FBS and 1% Penicillin-Streptomycin). The cells were incubated for 3 d at 37 • C and then washed twice with PBS and fixed-stained with 4% Formaldehyde/1% crystal violet solution; then, the viral plaques were counted. The difference between viral titer after curcumin treatment and untreated control was expressed as an inhibition percentage. Two independent experiments with two replicates each were conducted (n = 4).

Approximately 20 mL of total peripheral blood from each healthy adult donor (n = 3) was obtained by venipuncture in vacutainer tubes. PBMCs were isolated using the Ficoll-Histopaque density gradient method (Sigma-Aldrich Chemical Co., St. Louis, MO, USA) as previously described [77] .

To evaluate the anti-inflammatory effect of curcumin, the PBMCs were seeded in 24-well plates (1 × 10 6 cells/well) in RPMI1640 medium (Sigma-Aldrich) supplemented with 5% FBS. The cells were stimulated with curcumin (5 and 10 µg/mL) for 1 h. After pre-treatment, the SARS-CoV-2 was added at a MOI of 0.1 and incubated for 24 h, at 37 • C with 5% CO 2 . Three independent experiments with two replicates were conducted (n = 6). The cells without any treatment were used as negative controls.

The mRNA quantification for IL-1β, IL-6, IL-8, MCP-1, and TNF-α was carried out in PBMCs by real-time polymerase chain reaction (real-time PCR) as previously described [78] . Briefly, for total RNA extraction, the Direct-zol RNA Miniprep kit was used (Zymo Research, Orange, CA, USA). RNA concentration/purity were determined by spectrophotometry at 260-280 nm and cDNA was synthesized with 140 ng of RNA using the iScript cDNA synthesis kit (BIO-RAD, Hercules, CA, USA), according to the manufacturer's instructions.

Real-time PCR was performed using Maxima SYBR Green qPCR master mix kit (Fermentas, Glen Burnie, MD, USA). The mRNA PGK (phosphoglycerate kinase) was used as the housekeeping gene to normalize the RNA content ( Table 2 ). The amplification protocols were 40 cycles and standardized for each gene. For real-time RT-PCR analysis, the CFX Manager Version: 1.5.534.0511 software (Bio-Rad, Hercules, CA, USA) was used. Data are expressed as fold change, normalized against the constitutive gene and the untreated control, using the ∆∆Ct method, as previously reported [79] . 

Concentrations of IL-1β, IL-6, and IL-8 were quantified in PBMCs culture supernatants using ELISA kits (#437004, Biolegend, Thermofisher; #555220, BD Biosciences, San Jose, CA, USA; and #431504 Biolegend, Thermofisher, respectively) and according to the manufacturer's instructions.

All data were analyzed with GraphPad Prism (La Jolla, CA, USA). Data were presented as median ± IQR (interquartile range) or mean ± SEM (standard error of the mean), as indicated in each figure. Statistical differences were evaluated by Student s t-test or Mann-Whitney U test based on Shapiro-Wilk normality test. A p value ≤ 0.05 was considered significant. The EC50 (50% effective concentration) and CC50 (50% cytotoxic concentration) values were determined by non-linear regression analysis using a sigmoidal model. The selectivity index (SI) was calculated from the CC50/EC50 ratio.

This study was approved by the ethics committee of the Universidad Cooperativa de Colombia (Acta BIO106). It was carried out keeping good records, practicing good data collection and management, transparency of data-sharing, and realistic representation of study results. The data were analyzed anonymously. All donors were adults, read, and signed an informed consent. All research protocols were made according to the principles of the Declaration of Helsinki. Institutional Review Board Statement: This study was approved by the ethics committee of the Universidad Cooperativa de Colombia (Acta BIO106). It was carried out keeping good records, practicing good data collection and management, transparency of data-sharing, and realistic representation of study results. The data were analyzed anonymously. All donors were adults, read, and signed an informed consent. All research protocols were made according to the principles of the Declaration of Helsinki.

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.

Data Availability Statement: All data generated or analyzed during this study are included in this published article (and its supporting information files).

Addendum: A pneumonia outbreak associated with a new coronavirus of probable bat origin

Coronavirus diversity, phylogeny and interspecies jumping

Genetic Recombination, and Pathogenesis of Coronaviruses

Molecular Evolution of Human Coronavirus Genomes

Properties of Coronavirus and SARS-CoV-2

COVID-19: Epidemiology, Evolution, and Cross-Disciplinary Perspectives

The spike protein of SARS-CoV-A target for vaccine and therapeutic development

Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein

Genomic characterisation and epidemiology of 2019 novel coronavirus:Implications for virus origins and receptor binding

Existing antiviral options against SARS-CoV-2 replication in COVID-19 patients

COVID-19 and the immune system

Caracterización inmunológica de un grupo familiar colombiano con infección por SARS-CoV-2

Clinical features of patients infected with 2019 novel coronavirus in

Transcriptomic characteristics of bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID-19 patients

Natural product-derived phytochemicals as potential agents against coronaviruses: A review

The Hydroalcoholic Extract of Uncaria tomentosa (Cat's Claw) Inhibits the Infection of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) In Vitro

A review on antibacterial, antiviral, and antifungal activity of curcumin

Potential use of turmeric in COVID-19

Are curcuminoids effective C-reactive protein-lowering agents in clinical practice? Evidence from a meta-analysis

Curcumin inhibits mitogen stimulated lymphocyte proliferation, NFkappaB activation, and IL-2 signaling

Curcumin suppresses NLRP3 inflammasome activation and protects against LPS-induced septic shock

Curcumin Suppresses IL-1beta Secretion and Prevents Inflammation through Inhibition of the NLRP3 Inflammasome

Inhibition of dengue virus by curcuminoids

Curcumin inhibits Zika and chikungunya virus infection by inhibiting cell binding

Synergic effect of curcumin and its structural analogue (Monoacetylcurcumin) on anti-influenza virus infection

Inhibition of human immunodeficiency virus type-1 integrase by curcumin

Curcumin inhibits HIV-1 by promoting Tat protein degradation

Catechin and curcumin interact with S protein of SARS-CoV2 and ACE2 of human cell membrane:Insights from computational studies

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Targeting TMPRSS2 and Cathepsin B/L together may be synergistic against SARS-CoV-2 infection

Anti-infective Properties of the Golden Spice Curcumin

Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus

Emerging SARS-CoV-2 variants of concern and potential intervention approaches

In vitro and in silico anti-dengue activity of compounds obtained from Psidium guajava through bioprospecting

Curcumin inhibits influenza virus infection and haemagglutination activity

Inhibition of enveloped viruses infectivity by curcumin

Antiviral activity of four types of bioflavonoid against dengue virus type-2

Virtual screening and repurposing of FDA approved drugs against COVID-19 main protease

Curcumin-Gene Expression Response in Hormone Dependent and Independent Metastatic Prostate Cancer Cells

Curcumin modified silver nanoparticles for highly efficient inhibition of respiratory syncytial virus infection

Virucidal efficacy of treatment with photodynamically activated curcumin on murine norovirus bio-accumulated in oysters

Coronavirus membrane fusion mechanism offers a potential target for antiviral development

Host Cell Proteases Drive Early or Late SARS-CoV-2 Penetration

Discovery of a new function of curcumin which enhances its anticancer therapeutic potency

Specific plant terpenoids and lignoids possess potent antiviral activities against severe acute respiratory syndrome coronavirus

Curcumin prevents replication of respiratory syncytial virus and the epithelial responses to it in human nasal epithelial cells

Antiviral potential of curcumin

Potential Inhibitor of COVID-19 Main Protease (Mpro) From Several Medicinal Plant Compounds by Molecular Docking Study

Addressing the potential role of curcumin in the prevention of COVID-19 by targeting the Nsp9 replicase protein through molecular docking

Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization

Antiviral Strategies against PRRSV Infection

Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant

Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19

COVID-19: A New Virus, but a Familiar Receptor and Cytokine Release Syndrome

The many faces of the anti-COVID immune response

Nano-curcumin therapy, a promising method in modulating inflammatory cytokines in COVID-19 patients

A. NLRP3 at the interface of metabolism and inflammation

Curcumin Protects against Atherosclerosis in Apolipoprotein E-Knockout Mice by Inhibiting Toll-like Receptor 4 Expression

Curcumin alleviates macrophage activation and lung inflammation induced by influenza virus infection through inhibiting the NF-kappaB signaling pathway. Influenza Other Respir

Curcumin: An inflammasome silencer

Curcumin alleviates rheumatoid arthritis-induced inflammation and synovial hyperplasia by targeting mTOR pathway in rats

Curcumin modulation of high fat diet-induced atherosclerosis and steatohepatosis in LDL receptor deficient mice

The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse

Polymerized nano-curcumin attenuates neurological symptoms in EAE model of multiple sclerosis through down regulation of inflammatory and oxidative processes and enhancing neuroprotection and myelin repair

Molecular mechanism of curcumin on the suppression of cholesterol accumulation in macrophage foam cells and atherosclerosis

Structure-based drug designing for potential antiviral activity of selected natural products from Ayurveda against SARS-CoV-2 spike glycoprotein and its cellular receptor

Curcumin attenuates adhesion molecules and matrix metalloproteinase expression in hypercholesterolemic rabbits

IL-10-Dependent Amelioration of Chronic Inflammatory Disease by Microdose Subcutaneous Delivery of a Prototypic Immunoregulatory Small Molecule

Dose escalation of a curcuminoid formulation

Is cytotoxicity a determinant of the different in vitro and in vivo effects of bioactives? BMC Complement

Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions

Isolation and characterization of an early SARS-CoV-2 isolate from the 2020 epidemic in Medellín, Colombia

Antiviral activities of 2,6-diaminopurine-based acyclic nucleoside phosphonates against herpesviruses: In vitro study results with pseudorabies virus (PrV, SuHV-1)

Atorvastatin effectively inhibits late replicative cycle steps of SARS-CoV-2 in vitro

Insights into antiviral mechanisms of remdesivir, lopinavir/ritonavir and chloroquine/hydroxychloroquine affecting the new SARS-CoV-2

Effective Inhibition of SARS-CoV-2 Entry by Heparin and Enoxaparin Derivatives

Lower High-Density Lipoproteins Levels During Human Immunodeficiency Virus Type 1 Infection Are Associated with Increased Inflammatory Markers and Disease Progression

Inflammatory status and severity of disease in dengue patients are associated with lipoprotein alterations

Sulfasalazine as an Immunomodulator of the Inflammatory Process during HIV-1 Infection

We want to thank the Instituto Nacional de Salud, Bogotá-Colombia, for donating the Vero E6 cell line. The authors would like to thank Enago for the English language review.

The authors declare no conflict of interest.Sample Availability: Samples of the compounds are available from the authors.